Skip to main content

CORRECTION article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1562345

Immune Monitoring of Trabectedin Therapy in Refractory Soft Tissue Sarcoma Patients -the IMMUNYON Study

Provisionally accepted
Paulo Rodrigues-Santos Paulo Rodrigues-Santos *
  • Instituto de Imunologia, Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

This article is a correction to:

  1. Immune Monitoring of Trabectedin Therapy in Refractory Soft Tissue Sarcoma Patients -the IMMUNYON Study

    1. Read original article

The final, formatted version of the article will be published soon.

    The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.In the published article, there was an error. [Regarding the mistake in figure 6A, a correction needs to be made to two sentences in the RESULTS and DISCUSSION section].A correction has been made to [Results], [3.2.1 Immune monitoring of Trabectedin therapy and Progression-Free Survival], . This sentence previously stated: "[Immunophenotyping (Figure 5B) showed a significant decrease (p <0.05) for type 2 helper T cells (Th2), Figure 6A, and for conventional dendritic cells (cDCs), Figure 6B]"The corrected sentence appears below: "[Immunophenotyping (Figure 5B) showed an increase (p =0.0576) for type 2 helper T cells (Th2), Figure 6A]" A correction has been made to [Discussion], . This sentence previously stated: "[Regarding the immune monitoring associated with PFS, a significant decrease in eosinophils and decrease of type 2 helper T cells (Th2) and conventional dendritic cells (cDC) was associated with progression disease (PD) when compared to stable disease (SD)]"The corrected sentence appears below: "[Regarding the immune monitoring associated with PFS, a significant decrease in eosinophils, increase of type 2 helper T cells (Th2) and decrease conventional dendritic cells (cDC) was associated with progression disease (PD) when compared to stable disease (SD)]"In the published article, there was an error. [A mistake in the text inverting the sense of the sentence].A correction has been made to [Discussion], [Name of Sub-section if there is one], [Paragraph Number]. This sentence previously stated: "[In this study, decreased beta-transducin repeat containing (BTRC) and increased interferon alpha-1 (IFNA1) and interleukin 9 (IL9) gene expression were significantly associated with a better response to Trabectedin therapy.]"The corrected sentence appears below: "[In this study, decreased beta-transducin repeat containing (BTRC) and increased interferon alpha-1 (IFNA1) and interleukin 9 (IL9) gene expression were significantly associated with a worse response to Trabectedin therapy]"The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

    Keywords: Soft Tissue Sarcoma, Trabectedin, Immunophenotyping, Soluble factors, immune checkpoints, Progression free survival, Gene Expression Profiling

    Received: 17 Jan 2025; Accepted: 24 Jan 2025.

    Copyright: © 2025 Rodrigues-Santos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Paulo Rodrigues-Santos, Instituto de Imunologia, Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, 3004-504, Portugal

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.